TITLE

Research Capsules

PUB. DATE
October 2008
SOURCE
Pharmaceutical Representative;Oct2008, Vol. 38 Issue 10, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to drug research. Antiretroviral therapy tends to increase the average life expectancy of HIV-infected patients by 13 years. Eli Lilly and Co.'s Cialis, an erectile dysfunction drug, is said to be effective in relieving lower urinary tract symptoms. On the "Courage" study published in the "New England Journal of Medicine," angioplasty was found to have small advantage over drug treatment for patients with stable coronary disease.
ACCESSION #
34773787

 

Related Articles

  • Lilly wastes little time with launch of Cialis. Murphy, Tom // Indianapolis Business Journal;12/1/2003, Vol. 24 Issue 38, p3 

    Reports Eli Lilly and Co.'s launch of a drug for erectile dysfunction called Cialis. Approval of the Cialis by the U.S. Food and Drug Administration; Drug indication; Estimated amount needed by Eli Lilly to catch up with competitors Viagra from Pfizer Inc. and Levitra from Bayer Pharmaceuticals...

  • Cialis gets FDA approval for U.S. sales. Maurer, Katie // Indianapolis Business Journal;12/1/2003, Vol. 24 Issue 38, p41 

    Reports on the U.S. Food and Drug Administration's approval of the selling of Eli Lilly and Co. and Icos Corp.'s impotence drug Cialis in the U.S.

  • Lilly's Cialis overtakes iconic Viagra.  // Indianapolis Business Journal;7/18/2011, Vol. 32 Issue 20, p13 

    The article reports that erectile dysfunction (ED) drug Cialis from Eli Lilly and Co. overtook Viagra from Pfizer Inc. in terms of ED drugs' share in the global market.

  • Lilly developing oral treatment for erectile dysfunction. Rosa, Taina // Caribbean Business;3/22/2001, Vol. 29 Issue 12, p34 

    Reports on the treatment for impotence being developed by Eli Lilly & Co. Status of the testing of IC351, an investigational oral treatment; Side effects reported; Possibility of manufacturing the drug in Puerto Rico, as in the case of Pfizer Inc.'s Viagra.

  • Lilly, Sanofi seek to sell Cialis without prescription.  // Indianapolis Business Journal;6/2/2014, Vol. 35 Issue 14, p21 

    The article reports on the effort of French drug company Sanofi SA to sell American pharmaceutical company Eli Lilly and Co.'s erectile dysfunction drug Cialis without a prescription after the companies reached an agreement on marketing rights for the pills.

  • Eli Lilly's Anti-Impotence Drug Is Approved.  // Chemical Market Reporter;12/1/2003, Vol. 264 Issue 19, p14 

    Reports on the U.S. Food and Drug Administration's approval of the anti-impotence drug Cialis developed by drug company Eli Lilly & Co. for the treatment of erectile dysfunction. Revenue forecasts; Market competition.

  • Findings boost Lilly angioplasty drug.  // Indianapolis Business Journal;06/16/97, Vol. 18 Issue 13, p47 

    Reports on developments on Eli Lilly and Co.'s drug for angioplasty patients ReoPro. Increased popularity due to an editorial published in the `New England Journal of Medicine'; Approval for use by high-risk patients; Boost on its credibility and use.

  • Pfizer. Investor's Business Daily // Investors Business Daily;3/24/2015, pA02 

    The article reports that the biopharmaceutical firms Pfizer and Eli Lilly will resume the phase 3 chronic pain test for tanezumab.

  • Get ready for new drugs to treat erectile dysfunction. Gebhart, Fred // Drug Topics;6/2/2003, Vol. 147 Issue 11, p27 

    Reports on the release of drugs to treat erectile dysfunction in the U.S. Details on the action of the drugs tadalafil from Lilly and vardenafil from Bayer; Satisfaction rate reported by the patients; Duration of the drugs' effects.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics